[Immune response to HSP70-HBcAg(18-27) complex in HBV transgenic mice].
To study the cellular immune response to HSP70-HBcAg(18-27) complex in HBV transgenic mice. HSP70-HBcAg(18-27) complex was reconstituted in vitro, then it was injected into HBV transgenic mice to observe the cellular immune response. At the same time, we investigated whether HSP70-HBcAg(18-27) complex could generate antigen specific cytotoxic T lymphocyte responses in spleen cells. Our results demonstrated that HSP70-HBcAg(18-27) complex increased levels of CD4+ and CD8+ T cells in the spleens and peripheral blood of HBV transgenic mice, and the complex also activated dendritic and natural killer cells. HSP70-HBcAg(18-27) complex has an immunological antigenicity in raising the immunoresponse to chronic HBV infection in HBV transgenic mice. HSP70-HBcAg(18-27) complex might be considered as a candidate for further studies on its role as a therapeutic vaccine against chronic HBV infection in humans.